Annual Financial Report

RNS Number : 4301Y
Dechra Pharmaceuticals PLC
06 September 2022
 



Dechra Logo

 

 

6 September 2022

LEI: 213800J4UVB5OWG8VX82

 

 

Dechra® Pharmaceuticals PLC

(Dechra or the Company) 

 

 

Availability of 2022 Annual Report and Accounts

 

 

The 2022 Annual Report and Accounts is now available to view at www.dechra.com .

The following documents are scheduled to be mailed to registered shareholders of the Company on 19 September 2022:

· 2022 Annual Report and Accounts

· Notice of the 2022 Annual General Meeting; and

· Proxy Form for the 2022 Annual General Meeting.

 

In accordance with Listing Rule 9.6.1 a copy of each of these documents will be submitted to the National Storage Mechanism and will be available for viewing shortly after posting.

 

 

For further information, please contact:

Melanie Hall, Company Secretary

Dechra Pharmaceuticals PLC 

Telephone number: 01606 814730

 

 

 

Logo, company name Description automatically generated About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. 

 

For more information please visit: www.dechra.com

 

Trademarks

Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSSSISUMEESESU
UK 100

Latest directors dealings